0

NGS-based RNA-seq Market by End-user, Technology, and Geography - Forecast and Analysis 2023-2027

  • Published: Nov 2022
  • Pages: 158
  • SKU: IRTNTR74727
Technavio

Enjoy complimentary customisation on priority with our Enterprise License!

Safe and Secure SSL Encrypted

info
close
  • Single:

    One user only.
    Quick & easy download option

  • Enterprise:

    Unlimited user access (Within your organization)
    Complimentary Customization Included

2500 USD

The NGS-based RNA-seq market is estimated to grow at a CAGR of 15.34% between 2022 and 2027. The size of the market is forecast to increase by USD 3,753.73 million. The growth of the market depends on serval factors, including the increased adoption of next-generation sequencing methods, the technological advancement in sequencing platforms, and the availability of wide range of next-generation sequencing products

This report extensively covers market segmentation by end-user (academic and research centers, clinical research, pharma companies, and hospitals), technology (sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.

 What will the Size of the NGS-based RNA-seq Market During the Forecast Period?

NGS-based RNA-seq Market Size

To learn more about this report, Download Report Sample

Parent Market Analysis

Technavio categorizes the global NGS-based RNA-sequencing market as a part of the healthcare technology segment, which, in turn, is a part of the global healthcare market. The market includes the revenue generated from the sales of healthcare applications and IT systems; Internet-based healthcare tools (such as monitoring devices); and IT consulting services to clinics, hospitals, or businesses operating primarily in the healthcare sector. Our research report has extensively covered exteRNAl factors influencing the parent market growth during the forecast period.

NGS-based RNA-seq Market: Key Drivers, Trends, Challenges, and Customer Landscape

The increased adoption of next-generation sequencing methods is notably driving the market growth, although factors such as the lack of clinical validation on direct-to-consumer genetic tests may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

Key NGS-based RNA-seq Market Driver 

The increased adoption of next-generation sequencing methods is the key factor driving the global NGS-based RNA-sequencing market growth. The adoption of next-generation sequencing has increased in the past few years due to a decline in cost. Market players such as Illumina, Inc., and Roche have introduced breakthrough sequencing technologies that have led to cost and time reduction. Moreover, the number of service providers has increased, and these are delivering next-generation sequencing at a lower cost.

Rapid developments in next-generation sequencing techniques and the creation of a human genome database have allowed vendors to offer rapid diagnostic services and the capability to diagnose mutations and disorders in human gene sequences by using the complete human genome to study its structure, function, and organization. The above factors will increase the market growth during the forecast period.

Key NGS-based RNA-seq Market Trend

The advances in next-generation sequencing techniques are the primary trend in the global NGS-based RNA-sequencing market. The advent of next-generation sequencing techniques and the significant contribution of HGP have provided vendors and researchers with a critical resource on the function, structure, and organization of a complete set of human genomes. Rapid developments in the field of genomics have enabled next-generation sequencing techniques to be applied in various clinical environments, ranging from diagnosis to treatment outcomes of diseases such as cancer. They have also enabled researchers and medical practitioners to understand the variation in genetic sets that cause genetic disorders.

Moreover, The development of advanced technologies has helped to reduce the cost of testing as well as the turnaround time. Furthermore, the development of portable technologies by companies such as Oxford Nanopore Technologies, hybridization of available technologies such as SMRT sequencing and reversible semiconductor sequencing, and technological advances in bioinformatics software is expected to augment the growth of the global NGS-based RNA seq market during the forecast period.

Key NGS-based RNA-seq Market Challenge

The lack of clinical validation on direct-to-consumer genetic tests is a major challenge to the global NGS-based RNA-sequencing market growth. The clinical validity of direct-to-consumer genetic tests has been consistently questioned due to the presence of limited scientific evidence. This negatively impacts the commercialization of pre-disposition tests. Moreover, disease risk prediction provided by these tests does not include the overall context for risk assessment as it excludes the environmental and lifestyle factors, which play a critical role in increasing the risk of getting a disease.

Furthermore, the need for consumers to interpret complex results coupled with the lack of reliable scientific evidence makes it hard for them to understand the structural variation in the gene, and hence, they must rely on third parties, such as medical practitioners and genetic counselors, for reliable interpretation. This leads to additional consultation costs, which will increase the cost burden on consumers and hinder market growth during the forecast period.

Key NGS-based RNA-seq Market Customer Landscape

The report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

NGS-based RNA-seq Market Share by Geography

Global NGS-based RNA-seq Market Customer Landscape

 

Who are the Major NGS-based RNA-seq Market Vendors?                                     

Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.

agilent.com - The company offers NGS-based RNA-seq such as SureSelect Strand-Specific RNA Library Preparation for Whole-Transcriptome Sequencing.

The report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:

  • BGI Genomics Co. Ltd.
  • Brooks Automation Inc.
  • DNASTAR Inc.
  • Eurofins Scientific SE
  • F. Hoffmann La Roche Ltd.
  • Hamilton Bonaduz AG
  • Illumina Inc.
  • Precigen Inc.
  • Pacific Biosciences of California Inc.
  • PerkinElmer Inc.
  • PierianDx Inc.
  • Psomagen Inc.
  • QIAGEN NV

Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.

What is the Fastest-Growing Segment in the NGS-based RNA-seq Market?

The market share growth by the academic and research centers segment will be significant during the forecast period. Academic and research institutions are the primary revenue generators in the global NGS-based RNAseq market. Research laboratories from research institutes, universities, government institutions, biotechnology organizations, and pharmaceutical companies are included in the cluster. Next-generation sequencing products are being used in translational research across a wide range of scientific applications, from whole-genome sequencing to epigenetics. Such factors will drive the growth of the market during the forecast period.

NGS-based RNA-seq Market Size

Get a glance at the market contribution of various segments  Request a PDF Sample

The academic and research centers segment was valued at USD 950.35 million in 2017 and continue to grow by 2021The driving factors for the promotion of the market for next-generation sequencing-based RNA sequencing associated with research institutes are significant investments made by both private and public organizations. Ngs-based RNA sequencing technologies are being used in emerging fields such as agrigenomics and animal research to conduct genetic research to improve crop yield and nutritional composition. Ngs-based RNA sequencing technologies will play an important role in pharmacogenomics and infectious disease identification due to their contribution to drug discovery through target identification and compound optimization during the forecast period.

Which are the Key Regions for the NGS-based RNA-seq Market?

NGS-based RNA-seq Market Share by Geography

For more insights on the market share of various regions Request PDF Sample now!

APAC is projected to contribute 43% of market growth by 2023. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. North America was the largest revenue contributor to the global next-generation sequencing market in 2022, with the US being the leading country. The advent of next-generation sequencing has reduced the cost of genome sequencing, an essential step in a gene expression study, which increased the demand for early diagnosis of diseases such as cancer in the region. Moreover, the presence of conglomerate companies such as Illumina, Thermo Fisher Scientific, and PerkinElmer and the growing focus on genome mapping programs are also contributing significantly to the growth of the next-generation sequencing market in the region. 

This report forecasts the contribution of all the segments to the growth of the market. In addition, we have included the COVID-19 impact and the recovery strategies for each segment. COVID-19 led to an upsurge in the demand for North America. In 2021, business and industrial activities resumed with the relaxation of stringent lockdown restrictions due to the availability of COVID-19 vaccines and the vaccination drives carried out by the governments of different countries such as the US, Canada, and Mexico. Clinics and hospitals resumed NGS-based RNA seq procedures with proper safety and precautions at a faster pace, which increased the demand for RNA sequencing across the region. In addition, a major factor for NGS-based RNA seq market expansion is advancements in the field of molecular biology that have enhanced the sequencing procedures in 2022. Such factors have increased the demand for next-generation sequencing products and services in the region, which, in turn, is expected to drive the market during the forecast period. 

Segment Overview

The report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. The market has been segmented by end-user, technology, and region.

  • End-user Outlook (USD Million, 2017 - 2027)
    • Academic and research centers
    • Clinical research
    • Pharma companies
    • Hospitals
  • Technology Outlook (USD Million, 2017 - 2027)
    • Sequencing by synthesis
    • Ion semiconductor sequencing
    • Single-molecule real-time sequencing
    • Others
  • Region Outlook (USD Million, 2017 - 2027)
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW
      • Argentina
      • Australia
      • Rest of the World

NGS-based RNA-seq Market Scope

Report Coverage

Details

Page number

158

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 15.34%

Market growth 2023-2027

USD 3,753.73 million

Market structure

Fragmented

YoY growth (%)

15.1

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

APAC at 43%

Key countries

US, Singapore, UK, Germany, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Agilent Technologies Inc., BGI Genomics Co. Ltd., Brooks Automation Inc., DNASTAR Inc., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., Hamilton Bonaduz AG, Illumina Inc., Precigen Inc., Pacific Biosciences of California Inc., PerkinElmer Inc., PierianDx Inc., Psomagen Inc., QIAGEN NV, Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., and Zymo Research Corp.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request PDF sample

What are the Key Data Covered in this NGS-based RNA-seq Market Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the market between 2023 and 2027
  • Precise estimation of the size of the NGS-based RNA-seq market size and its contribution to the parent market
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
  • Thorough analysis of the market’s competitive landscape and detailed information about vendors
  • Comprehensive analysis of factors that will challenge the growth of NGS-based RNA-seq market vendors

 

We can help! Our analysts can customize this report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Technology
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global NGS-based RNA-seq market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on Global NGS-based RNA-seq market 2017 - 2021 ($ million)
    • 4.2 End User Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – End User Segment 2017 - 2021 ($ million)
    • 4.3 Technology Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Technology Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Acamedic and research centers - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Acamedic and research centers - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Acamedic and research centers - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Acamedic and research centers - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Acamedic and research centers - Year-over-year growth 2022-2027 (%)
    • 6.4 Clinical research - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Clinical research - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Clinical research - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Clinical research - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Clinical research - Year-over-year growth 2022-2027 (%)
    • 6.5 Pharma companies - Market size and forecast 2022-2027
      • Exhibit 42: Chart on Pharma companies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on Pharma companies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on Pharma companies - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on Pharma companies - Year-over-year growth 2022-2027 (%)
    • 6.6 Hospitals - Market size and forecast 2022-2027
      • Exhibit 46: Chart on Hospitals - Market size and forecast 2022-2027 ($ million)
      • Exhibit 47: Data Table on Hospitals - Market size and forecast 2022-2027 ($ million)
      • Exhibit 48: Chart on Hospitals - Year-over-year growth 2022-2027 (%)
      • Exhibit 49: Data Table on Hospitals - Year-over-year growth 2022-2027 (%)
    • 6.7 Market opportunity by End-user
      • Exhibit 50: Market opportunity by End-user ($ million)

    7 Market Segmentation by Technology

    • 7.1 Market segments
      • Exhibit 51: Chart on Technology - Market share 2022-2027 (%)
      • Exhibit 52: Data Table on Technology - Market share 2022-2027 (%)
    • 7.2 Comparison by Technology
      • Exhibit 53: Chart on Comparison by Technology
      • Exhibit 54: Data Table on Comparison by Technology
    • 7.3 Sequencing by synthesis - Market size and forecast 2022-2027
      • Exhibit 55: Chart on Sequencing by synthesis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 56: Data Table on Sequencing by synthesis - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Chart on Sequencing by synthesis - Year-over-year growth 2022-2027 (%)
      • Exhibit 58: Data Table on Sequencing by synthesis - Year-over-year growth 2022-2027 (%)
    • 7.4 Ion semiconductor sequencing - Market size and forecast 2022-2027
      • Exhibit 59: Chart on Ion semiconductor sequencing - Market size and forecast 2022-2027 ($ million)
      • Exhibit 60: Data Table on Ion semiconductor sequencing - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Chart on Ion semiconductor sequencing - Year-over-year growth 2022-2027 (%)
      • Exhibit 62: Data Table on Ion semiconductor sequencing - Year-over-year growth 2022-2027 (%)
    • 7.5 Single-molecule real-time sequencing - Market size and forecast 2022-2027
      • Exhibit 63: Chart on Single-molecule real-time sequencing - Market size and forecast 2022-2027 ($ million)
      • Exhibit 64: Data Table on Single-molecule real-time sequencing - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Chart on Single-molecule real-time sequencing - Year-over-year growth 2022-2027 (%)
      • Exhibit 66: Data Table on Single-molecule real-time sequencing - Year-over-year growth 2022-2027 (%)
    • 7.6 Others - Market size and forecast 2022-2027
      • Exhibit 67: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 68: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 69: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 70: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Technology
      • Exhibit 71: Market opportunity by Technology ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 73: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 75: Chart on Geographic comparison
      • Exhibit 76: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 77: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 78: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 79: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 80: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 81: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 82: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 83: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 84: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 93: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 94: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 95: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 96: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 UK - Market size and forecast 2022-2027
      • Exhibit 97: Chart on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 98: Data Table on UK - Market size and forecast 2022-2027 ($ million)
      • Exhibit 99: Chart on UK - Year-over-year growth 2022-2027 (%)
      • Exhibit 100: Data Table on UK - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 101: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 102: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 103: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 104: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 Singapore - Market size and forecast 2022-2027
      • Exhibit 105: Chart on Singapore - Market size and forecast 2022-2027 ($ million)
      • Exhibit 106: Data Table on Singapore - Market size and forecast 2022-2027 ($ million)
      • Exhibit 107: Chart on Singapore - Year-over-year growth 2022-2027 (%)
      • Exhibit 108: Data Table on Singapore - Year-over-year growth 2022-2027 (%)
    • 9.11 China - Market size and forecast 2022-2027
      • Exhibit 109: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 110: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 111: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 112: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 113: Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 114: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 116: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 117: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 118: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 119: Matrix on vendor position and classification
            • 12.3 Agilent Technologies Inc.
              • Exhibit 120: Agilent Technologies Inc. - Overview
              • Exhibit 121: Agilent Technologies Inc. - Business segments
              • Exhibit 122: Agilent Technologies Inc. - Key news
              • Exhibit 123: Agilent Technologies Inc. - Key offerings
              • Exhibit 124: Agilent Technologies Inc. - Segment focus
            • 12.4 BGI Genomics Co. Ltd.
              • Exhibit 125: BGI Genomics Co. Ltd. - Overview
              • Exhibit 126: BGI Genomics Co. Ltd. - Product / Service
              • Exhibit 127: BGI Genomics Co. Ltd. - Key offerings
            • 12.5 Brooks Automation Inc.
              • Exhibit 128: Brooks Automation Inc. - Overview
              • Exhibit 129: Brooks Automation Inc. - Business segments
              • Exhibit 130: Brooks Automation Inc. - Key offerings
              • Exhibit 131: Brooks Automation Inc. - Segment focus
            • 12.6 Eurofins Scientific SE
              • Exhibit 132: Eurofins Scientific SE - Overview
              • Exhibit 133: Eurofins Scientific SE - Business segments
              • Exhibit 134: Eurofins Scientific SE - Key news
              • Exhibit 135: Eurofins Scientific SE - Key offerings
              • Exhibit 136: Eurofins Scientific SE - Segment focus
            • 12.7 F. Hoffmann La Roche Ltd.
              • Exhibit 137: F. Hoffmann La Roche Ltd. - Overview
              • Exhibit 138: F. Hoffmann La Roche Ltd. - Business segments
              • Exhibit 139: F. Hoffmann La Roche Ltd. - Key news
              • Exhibit 140: F. Hoffmann La Roche Ltd. - Key offerings
              • Exhibit 141: F. Hoffmann La Roche Ltd. - Segment focus
            • 12.8 Hamilton Bonaduz AG
              • Exhibit 142: Hamilton Bonaduz AG - Overview
              • Exhibit 143: Hamilton Bonaduz AG - Product / Service
              • Exhibit 144: Hamilton Bonaduz AG - Key offerings
            • 12.9 Illumina Inc.
              • Exhibit 145: Illumina Inc. - Overview
              • Exhibit 146: Illumina Inc. - Business segments
              • Exhibit 147: Illumina Inc. - Key news
              • Exhibit 148: Illumina Inc. - Key offerings
              • Exhibit 149: Illumina Inc. - Segment focus
            • 12.10 Pacific Biosciences of California Inc.
              • Exhibit 150: Pacific Biosciences of California Inc. - Overview
              • Exhibit 151: Pacific Biosciences of California Inc. - Product / Service
              • Exhibit 152: Pacific Biosciences of California Inc. - Key offerings
            • 12.11 PerkinElmer Inc.
              • Exhibit 153: PerkinElmer Inc. - Overview
              • Exhibit 154: PerkinElmer Inc. - Business segments
              • Exhibit 155: PerkinElmer Inc. - Key news
              • Exhibit 156: PerkinElmer Inc. - Key offerings
              • Exhibit 157: PerkinElmer Inc. - Segment focus
            • 12.12 Psomagen Inc.
              • Exhibit 158: Psomagen Inc. - Overview
              • Exhibit 159: Psomagen Inc. - Product / Service
              • Exhibit 160: Psomagen Inc. - Key offerings
            • 12.13 QIAGEN NV
              • Exhibit 161: QIAGEN NV - Overview
              • Exhibit 162: QIAGEN NV - Product / Service
              • Exhibit 163: QIAGEN NV - Key news
              • Exhibit 164: QIAGEN NV - Key offerings
            • 12.14 Takara Bio Inc.
              • Exhibit 165: Takara Bio Inc. - Overview
              • Exhibit 166: Takara Bio Inc. - Product / Service
              • Exhibit 167: Takara Bio Inc. - Key offerings
            • 12.15 Tecan Trading AG
              • Exhibit 168: Tecan Trading AG - Overview
              • Exhibit 169: Tecan Trading AG - Business segments
              • Exhibit 170: Tecan Trading AG - Key offerings
              • Exhibit 171: Tecan Trading AG - Segment focus
            • 12.16 Thermo Fisher Scientific Inc.
              • Exhibit 172: Thermo Fisher Scientific Inc. - Overview
              • Exhibit 173: Thermo Fisher Scientific Inc. - Business segments
              • Exhibit 174: Thermo Fisher Scientific Inc. - Key news
              • Exhibit 175: Thermo Fisher Scientific Inc. - Key offerings
              • Exhibit 176: Thermo Fisher Scientific Inc. - Segment focus
            • 12.17 Zymo Research Corp.
              • Exhibit 177: Zymo Research Corp. - Overview
              • Exhibit 178: Zymo Research Corp. - Product / Service
              • Exhibit 179: Zymo Research Corp. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 180: Inclusions checklist
                • Exhibit 181: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 182: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 183: Research methodology
                • Exhibit 184: Validation techniques employed for market sizing
                • Exhibit 185: Information sources
              • 13.5 List of abbreviations
                • Exhibit 186: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              TechnavioINFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases
              Technavio

              TechnavioDATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts
              Technavio

              TechnavioREPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape
              Interested in this report?
              Get your sample now!
              NGS-based RNA-seq market growth will increase by $3753.73 million during 2023-2027.
              The ngs-based rna-seq market is expected to grow at a CAGR of 15.34% during 2023-2027.
              Technavio has segmented the ngs-based rna-seq market by end-user (Acamedic and research centers, Clinical research, Pharma companies, and Hospitals) ,technology (Sequencing by synthesis, Ion semiconductor sequencing, Single-molecule real-time sequencing, and Others) , and geography (North America, Europe, Asia, and Rest of World (ROW)).
              Agilent Technologies Inc., BGI Genomics Co. Ltd., Brooks Automation Inc., DNASTAR Inc., Eurofins Scientific SE, F. Hoffmann La Roche Ltd., Hamilton Bonaduz AG, Illumina Inc., Precigen Inc., Pacific Biosciences of California Inc., PerkinElmer Inc., PierianDx Inc., Psomagen Inc., QIAGEN NV, Takara Bio Inc., Tecan Trading AG, Thermo Fisher Scientific Inc., Zymo Research Corp. are a few of the key vendors in the ngs-based rna-seq market.
              North America will register the highest growth rate of 42.94% among the other regions. Therefore, the ngs-based rna-seq market in North America is expected to garner significant business opportunities for the vendors during the forecast period.
              The key factors driving the ngs-based rna-seq market growth are:
              • Increased adoption of next generation sequencing methods
              • Advances in next-generation sequencing techniques
              The ngs-based rna-seq market vendors should focus on grabbing business opportunities from the acamedic and research centers segment as it accounted for the largest market share in the base year.
              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?
              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis

              Certified ISO 9001 : 2015

              We are ISO recognized

              We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.

              We are GDPR and CCPA compliant

              We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.

              Safe and Secure SSL Encrypted
              Technavio

              info
              close
              • Single:

                One user only.
                Quick & easy download option

              • Enterprise:

                Unlimited user access (Within your organization)
                Complimentary Customization Included

              2500 USD

              Technavio Get the report (PDF) sent to your email within minutes.

              Subscribe & Save

              Get lifetime access to our
              Technavio Insights

              Customized Report as per your Business Needs

              • Our analysts will work directly with you and understand your needs
              • Get data on specified regions or segments, competitor and Vendors
              • Data will be formatted and presented as per your requirements
              • We offer $1000 worth of FREE customization at the time of purchase

              Let us help you make report more suited to your requirements.

              • Get a competitive breakdown as per your niche industry
              • Customize the data with various metrics that meet your business prerequisite
              • Understand Revenue Sources, Customers and many more
              • Details on Market Share
              • These customizations are done in a short amount of time by our analysts and industry experts
              Technavio
              Enquire Before Buying
              17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>